{
    "clinical_study": {
        "@rank": "18475", 
        "arm_group": [
            {
                "arm_group_label": "Hydrocortisone", 
                "arm_group_type": "Experimental", 
                "description": "little doses of hydrocortisone"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "No Intervention", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out whether stress doses of hydrocortisone attenuate\n      coagulation dysfunction in patients with septic shock. And discuss the probable mechanism by\n      which little doses of hydrocortisone influence coagulation system in sepsis."
        }, 
        "brief_title": "Effects of Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Coagulation Dysfunction in Septic Shock", 
            "Hemodynamic Improvement Induced by Hydrocortisone"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Shock", 
                "Shock, Septic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients were randomized to receive either low-dose hydrocortisone or matching\n      placebo.Severity of coagulopathy was estimated using ISTH DIC score. We determined the\n      complications and mortality in two groups, and analyzed the relationship between\n      hydrocortisone and coagulopathy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients(age\u226718y)\n\n          -  Admitted for septic shock were considered eligible if they had no life-threatening\n             systemic disease (ASA groups 1~3)\n\n        Exclusion Criteria:\n\n          -  Lactation\n\n          -  Mental disorders\n\n          -  Disseminated cancer\n\n          -  Secondary cancers\n\n          -  Inflammatory bowel disease, or diseases hindering epidural analgesia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "78 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02114710", 
            "org_study_id": "2009NLY078"
        }, 
        "intervention": {
            "arm_group_label": "Hydrocortisone", 
            "description": "Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs", 
            "intervention_name": "Hydrocortisone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Hydrocortisone", 
                "Hydrocortisone-17-butyrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "coagulopathy", 
            "hydrocortisone", 
            "organ failure"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "number_of_arms": "2", 
        "official_title": "Study of Little Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: National Natural Science Foundation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "death", 
            "safety_issue": "Yes", 
            "time_frame": "30 days after inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02114710"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Nanjing PLA General Hospital", 
            "investigator_full_name": "Gao Tao", 
            "investigator_title": "Nanjing PLA General Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "clinical perioperative complications", 
                "safety_issue": "Yes", 
                "time_frame": "30 days after inclusion"
            }, 
            {
                "description": "MODS SOFA score", 
                "measure": "clinical complications", 
                "safety_issue": "Yes", 
                "time_frame": "30 days after inclusion"
            }
        ], 
        "source": "Nanjing PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nanjing PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}